Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH Agonist
Phase 3ActiveDevelopment Stage
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Oct 9, 2020 → Mar 25, 2028
About Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH Agonist
Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH Agonist is a phase 3 stage product being developed by Roche for Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04546009. Target conditions include Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.
What happened to similar drugs?
1 of 2 similar drugs in Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04546009 | Phase 3 | Active |
Competing Products
20 competing products in Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer